Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 24, 2023 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
May 08, 2023 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan Appointment of chief medical officer and key leaders across...
May 01, 2023 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
April 13, 2023 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
April 06, 2023 07:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
March 07, 2023 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
March 02, 2023 21:15 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
March 01, 2023 16:17 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Commencement of Public Offering of Common Stock

REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
February 27, 2023 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805...
February 21, 2023 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right